These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 8432585

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.
    Kossaczka Z, Lin FY, Ho VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB, Trach DD, Karpas A, Hunt S, Bryla DA, Schneerson R, Robbins JB, Szu SC.
    Infect Immun; 1999 Nov; 67(11):5806-10. PubMed ID: 10531232
    [Abstract] [Full Text] [Related]

  • 8. Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines.
    Konadu E, Robbins JB, Shiloach J, Bryla DA, Szu SC.
    Infect Immun; 1994 Nov; 62(11):5048-54. PubMed ID: 7927787
    [Abstract] [Full Text] [Related]

  • 9. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
    Salman M, St Michael F, Ali A, Jabbar A, Cairns C, Hayes AC, Rahman M, Iqbal M, Haque A, Cox AD.
    J Immunol Methods; 2017 Nov; 450():27-33. PubMed ID: 28735760
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge.
    Fattom AI, Sarwar J, Ortiz A, Naso R.
    Infect Immun; 1996 May; 64(5):1659-65. PubMed ID: 8613375
    [Abstract] [Full Text] [Related]

  • 12. Vaccine potential of Pseudomonas aeruginosa O-polysaccharide-toxin A conjugates.
    Cryz SJ, Lang AB, Sadoff JC, Germanier R, Fürer E.
    Infect Immun; 1987 Jul; 55(7):1547-51. PubMed ID: 3110065
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines.
    Fattom A, Cho YH, Chu C, Fuller S, Fries L, Naso R.
    Vaccine; 1999 Jan; 17(2):126-33. PubMed ID: 9987146
    [Abstract] [Full Text] [Related]

  • 15. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
    Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, Kossaczka Z, Bryla DA, Shiloach J, Robbins JB, Schneerson R, Szu SC.
    N Engl J Med; 2001 Apr 26; 344(17):1263-9. PubMed ID: 11320385
    [Abstract] [Full Text] [Related]

  • 16. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.
    Devi SJ, Schneerson R, Egan W, Ulrich TJ, Bryla D, Robbins JB, Bennett JE.
    Infect Immun; 1991 Oct 26; 59(10):3700-7. PubMed ID: 1716613
    [Abstract] [Full Text] [Related]

  • 17. Conjugates of group A and W135 capsular polysaccharides of neisseria meningitidis bound to recombinant Staphylococcus aureus enterotoxin C1: preparation, physicochemical characterization, and immunological properties in mice.
    Jin Z, Bohach GA, Shiloach J, Norris SE, Freedberg DI, Deobald C, Coxon B, Robbins JB, Schneerson R.
    Infect Immun; 2005 Dec 26; 73(12):7887-93. PubMed ID: 16299279
    [Abstract] [Full Text] [Related]

  • 18. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines.
    Szu SC, Taylor DN, Trofa AC, Clements JD, Shiloach J, Sadoff JC, Bryla DA, Robbins JB.
    Infect Immun; 1994 Oct 26; 62(10):4440-4. PubMed ID: 7927707
    [Abstract] [Full Text] [Related]

  • 19. Use of Pseudomonas aeruginosa toxin A in the construction of conjugate vaccines and immunotoxins.
    Cryz SJ, Fürer E, Sadoff JC, Germanier R, Pastan I, Willingham MC, FitzGerald DJ.
    Rev Infect Dis; 1987 Oct 26; 9 Suppl 5():S644-9. PubMed ID: 3120274
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.